Aura Competitors
| AURA Stock | USD 5.57 0.06 1.09% |
Aura Biosciences vs Solid Biosciences Correlation
Average diversification
The correlation between Aura Biosciences and SLDB is 0.16 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Aura Biosciences and SLDB in the same portfolio, assuming nothing else is changed.
Moving against Aura Stock
| 0.46 | VALN | Valneva SE ADR | PairCorr |
| 0.43 | GXEA | Galapagos NV Earnings Call Next Week | PairCorr |
| 0.42 | 8VP1 | AVRICORE HEALTH INC | PairCorr |
| 0.41 | DRTS | Alpha Tau Medical | PairCorr |
Aura Biosciences Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Aura Biosciences and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Aura and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Aura Biosciences does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Aura Stock performing well and Aura Biosciences Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Aura Biosciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ENGN | 3.80 | 0.16 | 0.04 | 0.14 | 4.53 | 8.59 | 22.57 | |||
| LBRX | 3.91 | 0.88 | 0.19 | (0.98) | 3.47 | 10.43 | 23.59 | |||
| ALT | 3.90 | 0.22 | 0.04 | 0.38 | 5.16 | 9.80 | 33.75 | |||
| QSI | 3.49 | (0.83) | 0.00 | (0.19) | 0.00 | 7.09 | 20.82 | |||
| RCKT | 2.86 | 0.03 | 0.02 | 0.08 | 3.25 | 8.04 | 19.80 | |||
| DSGN | 3.24 | 0.49 | 0.12 | 0.64 | 3.51 | 8.91 | 18.90 | |||
| ANNX | 4.13 | 0.88 | 0.21 | 3.41 | 3.51 | 11.30 | 35.10 | |||
| KRRO | 5.02 | (0.63) | 0.00 | (0.06) | 0.00 | 10.98 | 79.86 | |||
| DBVT | 4.51 | 0.87 | 0.17 | (1.84) | 4.12 | 10.53 | 36.36 | |||
| SLDB | 3.37 | 0.58 | 0.18 | 0.35 | 3.09 | 11.36 | 21.71 |
Cross Equities Net Income Analysis
Compare Aura Biosciences and related stocks such as enGene Holdings Common, LB Pharmaceuticals Common, and Altimmune Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LBRX | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (6.3 M) | (63.1 M) | (56.8 M) | (54 M) |
| ALT | 277.3 K | (3.8 M) | (4.9 M) | (11.7 M) | (10 M) | (3.4 M) | 193.9 M | (46.4 M) | (39.2 M) | (20.5 M) | (49 M) | (97.1 M) | (84.7 M) | (88.4 M) | (95.1 M) | (85.6 M) | (81.3 M) |
| QSI | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (36.6 M) | (95 M) | (132.4 M) | (96 M) | (101 M) | (90.9 M) | (95.5 M) |
| RCKT | (6.1 M) | (6.1 M) | (6.1 M) | (7.6 M) | (9.5 M) | (68 M) | (42.9 M) | (29.5 M) | (74.5 M) | (83.2 M) | (146.7 M) | (169.1 M) | (221.9 M) | (245.6 M) | (258.7 M) | (232.9 M) | (221.2 M) |
| DSGN | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (8.3 M) | (35.5 M) | (58.6 M) | (66.9 M) | (49.6 M) | (44.6 M) | (46.9 M) |
| ANNX | (18.7 M) | (18.7 M) | (18.7 M) | (18.7 M) | (18.7 M) | (18.7 M) | (18.7 M) | (18.7 M) | (18.3 M) | (37.2 M) | (62.7 M) | (127.8 M) | (138.3 M) | (134.2 M) | (138.2 M) | (124.4 M) | (130.6 M) |
| KRRO | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (19.2 M) | (18.7 M) | (26.5 M) | (84.7 M) | (58 M) | (81.2 M) | (83.6 M) | (75.2 M) | (79 M) |
| DBVT | (6.1 M) | (9.4 M) | (17 M) | (26.6 M) | (29.1 M) | (48.5 M) | (126.3 M) | (177.2 M) | (190.3 M) | (172 M) | (159.6 M) | (97.8 M) | (96.3 M) | (72.7 M) | (113.7 M) | (102.3 M) | (107.5 M) |
| SLDB | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (21.5 M) | (52.1 M) | (74.8 M) | (117.2 M) | (88.3 M) | (72.2 M) | (86 M) | (96 M) | (124.7 M) | (112.2 M) | (117.8 M) |
Aura Biosciences and related stocks such as enGene Holdings Common, LB Pharmaceuticals Common, and Altimmune Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Aura Biosciences financial statement analysis. It represents the amount of money remaining after all of Aura Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Aura Biosciences Competitive Analysis
The better you understand Aura Biosciences competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Aura Biosciences' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Aura Biosciences' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Aura Biosciences Competition Performance Charts
Five steps to successful analysis of Aura Biosciences Competition
Aura Biosciences' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Aura Biosciences in relation to its competition. Aura Biosciences' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Aura Biosciences in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Aura Biosciences' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Aura Biosciences, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Aura Biosciences position
In addition to having Aura Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Momentum Thematic Idea Now
Momentum
Large corporations operating in software, education, financial and car manufacturing industries. The Momentum theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Momentum Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Aura Biosciences Correlation with its peers. For information on how to trade Aura Stock refer to our How to Trade Aura Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aura Biosciences. If investors know Aura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Aura Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Aura Biosciences requires distinguishing between market price and book value, where the latter reflects Aura's accounting equity. The concept of intrinsic value - what Aura Biosciences' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Aura Biosciences' price substantially above or below its fundamental value.
Understanding that Aura Biosciences' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Aura Biosciences represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Aura Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.